Gene-to-Structure and FastLane™ Structures

SARomics Biostructures' services include:
• Gene-to-Structure: expression, purification, crystallization and structure determination
• Protein-ligand co-crystallization and structure determination
• Protein characterization (folding, solubility, aggregation, thermo-stability, etc.)

SARomics Biostructures' FastLane™ off-the-shelf structure library includes more than 169 kinases, phosphatases, epigenetic targets and other proteins which can be delivered in complex with customers' ligands within 2 to 12 weeks. Our strategic location in close vicinity to the new Swedish synchrotron MAX IV in Lund provides us with quick access to beamlines, minimizing the need for crystal transportation to remote synchrotrons and allowing us to offer quick services at highly competitive prices. Please view below the lists of available structures or contact us for the discussion of your project.


CK2 kinase 3D structure
Vps34 kinase 3D structure
PFKFB3 3D structure
HSP90 3D structure
Cathepsin C 3D structure
My Image
ATAD2 Bromodomain 3D structure
Human DHODH
Aldose reductase 3D structure
PDE4D2 3D structure
M. tuberculosis beta-lactamase (BlaC) 3D structure
M. tuberculosis beta-lactamase (BlaC) 3D structure
M. tuberculosis beta-lactamase (BlaC) 3D structure

Our premium class of FastLane™ structures includes purified proteins stored in our lab and ready to be co-crystallized with customer's compounds. Delivery time 2 to 6 weeks. In most cases the ability to obtain co-crystal structures with ligands has been demonstrated. Please click the link below for the full list.


FastLane™ Structures

Our library of FastLane™ (off-the-shelf) structures includes about 140 proteins ready to be expressed, purified and crystallized according to existing verified protocols. The Library currently includes more than 50 kinases, a large collection of phosphatases, more than 40 epigenetic targets and other proteins. Ligand complex structures can be delivered within 6 to 12 weeks.

You may also be interested in our drug discovery platform, which uses fragment screening and fragment-based drug discovery!